Described is a combination of (i) a multifunctional antibody having specificity for an antigen present on a tumor cell and having specificity for an antigen present on a natural killer (NK) cell and (ii) at least one agent modulating an immune checkpoint molecule for the treatment of a tumor. The antibody may be a bispecific CD30/CD16 antibody and the agent can be anti-CTLA-4, anti-PD1 and ant-CD 137.